Benox

Quick links to important sections

Benox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benox

Property Description
Active Ingredient Oxybuprocaine (Benoxinate)
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class Local Anesthetic (Ester-Type)
Origin Synthetic Compound
Route of Administration Topical Ophthalmic

Benox is a synthesized pharmaceutical preparation strictly intended for surface application to the eye, recognized as a topical ophthalmic local anesthetic. Its primary purpose is to induce a temporary numbing of sensation on the corneal and conjunctival surfaces, a function utilized for in-office eye examinations.

Composition and Classification

The medicine's activity is derived from the single active ingredient, Oxybuprocaine hydrochloride, which is also frequently identified by the chemical synonym Benoxinate hydrochloride. This compound is an ester-type local anesthetic, a classification characterized by its mechanism of action via the reversible blockade of nerve impulse conduction. The formulation is presented as a sterile solution—commonly eye drops—in an aqueous base, a form intended for compatibility with the sensitive ocular surface. This medicine is typically a prescription-only (Rx) product, reflecting its intended use by healthcare professionals.

General Purpose and Clinical Role

The role of this preparation is to provide superficial anesthesia, thereby reducing discomfort and reflexive responses during examinations. This capability allows medical professionals to conduct various diagnostic tests, such as measuring intraocular pressure (tonometry), or to perform minor interventional tasks that require the eye's surface to be insensate. As a surface anesthetic, the compound acts to quickly numb the cornea and conjunctiva to allow for these procedures. The use of Oxybuprocaine/Benoxinate as a preparatory agent is intended to meet these clinical requirements.

What side effects are possible with Benox?

Possible Side Effects and Safety Information

The safety profile of Benox is largely characterized by local effects related to its action on the eye. Factual information on potential side effects and safety considerations is derived from governmental regulatory documents.


Adverse Reactions

The most common ocular adverse events reported include stinging, burning, and redness of the conjunctiva (ocular hyperemia). Other documented reactions involve general eye irritation, blurred vision, and punctate keratitis.

Classification Event Examples (Ocular)
Most Common Stinging, burning, conjunctival redness
Other Reactions Eye irritation, blurred vision, punctate keratitis

Serious and Clinically Significant Risks

Official labeling emphasizes two serious risks that require particular caution:

  • Corneal Toxicity: Prolonged use or abuse of Benox may lead to corneal epithelial toxicity. This condition can manifest as epithelial defects and may progress to permanent opacification of the cornea, potentially resulting in accompanying visual loss.
  • Corneal Injury due to Insensitivity: Following application, the eye's corneal reflex is temporarily lost. This anesthetic effect creates a risk of accidental corneal injury because the eye is insensitive to touch or foreign bodies for approximately 20 minutes after administration.

Specific Population Safety Considerations

  • Pregnancy: There is no established data on the use of this drug in pregnant women to determine the risk to the fetus. It should be used during pregnancy only if the clinical need is clearly necessary.
  • Lactation: Data is absent regarding the presence of Benox in human milk, the effects on a breastfed infant, or the effects on milk production.
  • Pediatric Use: The safety and effectiveness have been established for use in pediatric patients.

Benox is contraindicated in individuals with a known hypersensitivity to any component of the product.

Overdose and Emergency Response

The official regulatory profile for Benox (Oxybuprocaine/Benoxinate) overdose outlines risks associated with both systemic exposure and chronic local overuse. Systemic toxicity, which may occur following accidental ingestion of the ophthalmic solution, is characterized by signs of Central Nervous System (CNS) effects. Documented acute manifestations include confusion, agitation, disorientation, and paraesthesia, and in severe cases, life-threatening outcomes such as seizures, respiratory depression, and coma. Cardiovascular signs, including a slow heartbeat, are also documented.

Immediate medical action is required for any accidental swallowing of the solution, irrespective of whether symptoms are present. Regulatory authorities mandate that individuals should seek immediate medical attention, contacting the Poisons Information Centre or going straight to the Emergency Department. For acute ocular overdose (administering too many drops), the required action is to immediately rinse the affected eye(s) with warm water.

The labeling also addresses chronic, non-procedural overuse, warning of potential local ocular abuse toxicity. This prolonged exposure can lead to severe local injury, including corneal epithelial defects, keratitis, and the risk of permanent corneal damage with accompanying visual loss. Management of established systemic overdose is defined as symptomatic and supportive, with no specific antidote explicitly documented in the official prescribing information.

Therapeutic Uses of Benox

Benox (Oxybuprocaine/Benoxinate) is indicated for use in adult and pediatric patients requiring a topical ophthalmic anesthetic agent.

Relief of Acute Procedural Pain and Discomfort

Benox is used for facilitating the management of symptoms related to physical discomfort, specifically the sharp pain and reflexive responses that result from contact with the eye during essential examinations. This symptomatic support contributes to improved comfort for the patient, assisting with the execution of diagnostic tests.

Anesthesia for Minor Eye Interventions

The preparation is utilized in clinical settings that involve acute or unstable symptom patterns, including tonometry (eye pressure checks), the removal of superficial foreign bodies, and providing support during pediatric screenings and acute postoperative discomfort after certain laser surgeries. This supportive relief assists with maintaining functional stability by easing distress.


Quick Fact: Relief for Acute Ocular Pain

“The supportive relief from acute pain helps medical professionals acquire the data needed for diagnosis and monitoring.”

Regulatory References

  1. DailyMed, a service of the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Benox?

This section outlines the officially documented population eligibility and restrictions for using Benoxinate/Oxybuprocaine, based strictly on government regulatory labeling.


Contraindicated Populations

The medicine is contraindicated (absolutely prohibited) for use in patients with a known hypersensitivity or allergy to Benoxinate/Oxybuprocaine, any other components of the ophthalmic solution, or to topical anesthetics belonging to the p-aminobenzoic acid group. Use is also contraindicated in patients presenting with an eye infection.


Age-Group and Condition-Specific Eligibility

Population Regulatory Status Restriction/Caution
Adults Established use. None specified.
Pediatrics Established (US Label); Not Recommended (EU/Regional SmPC). Varies by regulatory region.
Cardiac/Hepatic Approved, but Use with Caution. Used cautiously and sparingly in patients with cardiac disease, hyperthyroidism, or hepatic diseases.
Pregnant/Lactating Not Established/Caution. Given only if clearly needed; Caution advised during breastfeeding as distribution into milk is unknown.

Mandatory Usage Restriction

The eligibility for all populations is strictly limited by the duration of use. Prolonged or frequent use is not recommended as it is officially documented to cause severe and irreversible damage to the cornea, including opacification.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Benox (Oxybuprocaine/Benoxinate) is officially documented by regulatory authorities, focusing on pharmacokinetic and pharmacodynamic effects with specific co-administered agents. Due to its topical ophthalmic route of administration, the spectrum of systemic interactions is limited, but specific drug-drug interactions are noted.

Pharmacologic Interaction Mechanisms

Category Interacting Substance Official Interaction Description
Pharmacokinetic Anticholinesterases (Medicinal Products) Co-administration may result in the prolongation of the effects of Oxybuprocaine, officially described as resulting from metabolic inhibition (reduced clearance).
Pharmacodynamic Suxamethonium (Neuromuscular Blocking Agent) The active substance may competitively enhance the neuromuscular blocking action of Suxamethonium.
Pharmacodynamic Sulfonamides (Antibacterial Agents) The antimicrobial action of sulfonamide agents may be reduced by co-administration.

Restrictions and Incompatibilities

The formulation is chemically incompatible with certain agents. The official regulatory notes state that the solution should not be co-administered with alkaline substances or solutions containing silver or mercury salts, as these compounds can compromise the integrity and stability of the ophthalmic solution. No specific interactions with food, alcohol, or herbal products are explicitly documented in regulatory labeling.

Mechanism of Action

Benox (benoxinate/oxybuprocaine) functions as an ester-type local anesthetic that targets voltage-gated sodium channels (Nav channels) located within neuronal membranes, specifically accumulating at peripheral sensory nerve endings, such as those in the cornea and conjunctiva. The drug acts as an inhibitor by physically binding to the intracellular portion of the sodium channel protein.

This molecular interaction causes a stabilization of the neuronal cell membrane, which in turn decreases the membrane's permeability to sodium ions. The resulting inhibition of sodium ion influx prevents the necessary depolarization required to reach the threshold for action potential generation. This blockade effectively prevents the initiation and subsequent propagation of nerve impulses along the axon. The downstream cascade is the systemic modulation of afferent sensory nerve signaling, resulting in a localized interruption of signal transmission to the central nervous system.

Dosage and Administration Information

Benoxinate hydrochloride, often combined with fluorescein sodium, is a prescription medication indicated for topical ophthalmic instillation (use in the eye) for short-term procedures. It is supplied as a sterile ophthalmic solution.

Official Administration Guidelines

The following instructions reflect the requirements for use:

Entity Official Instruction
Route of Administration Topical ophthalmic use only. Not for injection.
Standard Dosing Instill 1 to 2 drops topically in the eye.
Frequency/Timing Administer as needed to achieve adequate anesthesia for the procedure.
Duration of Effect Maximal corneal anesthesia typically occurs within 5–45 seconds and lasts approximately 20 minutes after a single administration.

Procedural Requirements

Administration must follow strict procedural steps to maintain product sterility and ensure patient safety while the eye is insensitive.

  • Dose Instillation: Instill the labeled dose of 1 to 2 drops into the eye.
  • Contamination Avoidance: Avoid touching the tip of the sterile dropper used to dispense the solution to the eye or any other surface.
  • Pediatric Use: The safety and effectiveness have been established for pediatric patients, and the standard dosing applies.

This medication is structured for use only as a short-acting, localized anesthetic in the context of an ophthalmic procedure. The required topical application and precise drop volume ensure usage remains strictly within established clinical parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benox

Evidence for Use During Eye Examinations and Procedures

Benox (Oxybuprocaine/Benoxinate) was studied in research exploring its use for inducing temporary surface anesthesia, a state necessary for certain diagnostic procedures and minor interventions. The research includes controlled trials and regulatory documents that have reviewed the medicine’s established use, often comparing its action to other agents. The studies monitored the onset time and duration of the numbing effect on the cornea, which was measured using specific instruments to determine the Corneal Touch Threshold (CTT). Findings describe patterns observed in these studies indicating a quick onset, with the measurement of outcomes related to physical discomfort being tracked quickly after application. The research provides insight into short-term changes in sensation, reporting that the observed duration of the numbing effect was typically short, generally lasting only 20 to 30 minutes following administration.

Research Focus on Post-Surgical Symptom Management

Research has explored a specific, short-term use of Benox, with studies evaluating its use during the period of acute discomfort in the immediate recovery phase following certain types of corneal surgery, such as photorefractive keratectomy (PRK). This research was evaluated in prospective Randomized Controlled Trials (RCTs). These trials examined patient-reported outcomes describing perceived discomfort using standardized pain scales during the first few days after the procedure. Findings from some trials reported patterns regarding pain scores measured during the first few days following surgery. However, the evidence applies only to studies using specific formulations, often preservative-free, and was designed for a limited follow-up duration.

Duration of Effect and Long-Term Research Gaps

Long-term effects are not fully established because the medication is intended and labeled only for single-use or very short-duration applications. There is limited information for long-term outcomes or the consequences of using the agent for an extended duration, as this falls outside its intended use.

Key Studies & References

  1. Oxybuprocaine hydrochloride Ophthalmic Solution: DailyMed Drug Label Information

Frequently Asked Questions (FAQ)

Common questions about Benox (FAQ)

Q: How long does Benox stay in your system after you stop taking it?

Studies on the drug’s breakdown in the body, known as pharmacokinetics, indicate that the active substance is rapidly processed by enzymes. Official information describes the half-life in human plasma as very short, typically lasting about 2 to 3 minutes after any systemic absorption.


Q: Is Benox known to be safe to use during pregnancy (as described in official documents)?

Regulatory documents state there is no established data regarding the use of this medicine in pregnant women to fully determine the risk to a fetus. Therefore, official guidance notes that the drug is described as appropriate for use during pregnancy only if a healthcare professional determines the clinical need is clearly necessary.


Q: Is Benox approved for children?

The regulatory status regarding use in children can vary by region. The US label indicates that safety and effectiveness have been established for pediatric patients. However, some regional prescribing information may state that use in children is not recommended.


Q: What happens if I accidentally take two doses of Benox?

Benox is intended for single, short-term professional use only. Official warnings highlight risks associated with overuse, which include accidental corneal injury because the eye is numb, and risks of corneal toxicity from prolonged or frequent use of the eye drops. Concerns about administration should be directed to the healthcare professional managing the procedure.


Q: Does taking Benox cause sensitivity to the sun?

Sensitivity to light, known as photophobia, is listed in official documents as one of the adverse reactions that have been reported with the use of this medicine.


Q: What is the typical duration of treatment with Benox?

The official documentation describes this medicine as strictly intended for single-use or very short-duration applications for specific ophthalmic procedures. The medicine is not designed or labeled for extended or long-term use. Official documents state that long-term effects are not established.


Q: What kind of drugs or supplements should I check for interaction with Benox?

Official prescribing information describes interactions with medicines such as Anticholinesterases, Suxamethonium, and Sulfonamides. It is also described as chemically incompatible with certain compounds, including alkaline substances and solutions containing silver or mercury salts.


Q: Is it necessary to avoid alcohol completely while taking Benox?

The official regulatory labeling does not explicitly document any specific interactions between Benox and alcohol.


Q: Do I need to change my diet while I am using Benox?

Official regulatory labeling does not explicitly document any specific interactions between Benox and food. This means no specific dietary requirements are noted in the product information.


Q: Is there a generic version of Benox available?

Generic availability can vary depending on the country and the exact formulation being discussed. Official data for the US product combining benoxinate hydrochloride and fluorescein sodium indicates that a generic version is not currently available.


Q: Are there any specific warning signs I should look out for when starting Benox?

Warnings are provided regarding the risk of accidental corneal injury because the eye is temporarily insensitive after application, and the risks of corneal toxicity from prolonged use. Official guidance describes seeking medical attention if symptoms of a severe allergic reaction occur.


Q: If I miss a day of Benox, what does the official guidance say?

This medication is intended and labeled for single-use or very short-duration applications in a professional setting. Because of this, the concept of 'missing a day' of a prescribed course is not applicable to its official use.


Q: Do studies suggest that the effectiveness of Benox changes over time?

Research has focused on monitoring the short duration of the numbing effect, which typically lasts around 20 to 30 minutes. Since the drug is not intended for extended use, regulatory information on whether effectiveness changes over a long period is limited.


Q: Is there a specific time of day Benox is usually taken?

Official administration guidance states that the medicine should be administered 'as needed' to achieve adequate anesthesia for the ophthalmic procedure. There is no requirement for it to be taken at a specific time of day.


Q: Why do some people say they felt different right away after taking Benox?

The onset of the numbing effect is very rapid, usually within 5 to 45 seconds after the drops are instilled. Additionally, common immediate effects upon instillation include transient stinging and burning, which are normal, expected reactions.


Q: Can Benox interact with herbal supplements like St. John's Wort?

The official regulatory labeling does not explicitly document any specific interactions between Benox and herbal products, including St. John's Wort.


Q: Is it described as safe to drive while using Benox?

Official documents state that patients are advised not to drive or operate hazardous machinery until normal vision is restored. This guidance is provided because blurred vision is a listed adverse reaction of the medicine.


Q: Are there different strengths or formulations of Benox available?

Yes, official product information indicates the medicine is available as a sterile ophthalmic solution in different strengths. It may also be formulated with or without other compounds, such as fluorescein sodium.


Q: Does Benox have any known interaction with grapefruit?

The official regulatory labeling does not explicitly document any specific interactions between Benox and foods, including grapefruit.


Q: How long does it typically take for side effects of Benox to go away after stopping the drug?

Common local side effects such as stinging, burning, and blurred vision are described as transient. Official information indicates these effects and the return of corneal sensitivity typically wear off after approximately one hour.

How should Benox be stored and disposed of?

Official Storage and Disposal Requirements

The ophthalmic solution containing Benoxinate must be stored and handled according to strict regulatory guidelines to maintain its stability.

Storage Conditions

Condition Requirement
Temperature (Unopened) Store in a refrigerator at 2 C to 8 C (36 F to 46 F). Do not freeze.
Container & Protection Keep the multi-dose container tightly closed and protected from light.
Stability (Post-Opening) If stored at room temperature, use within one month of opening. If kept refrigerated, use until the printed expiration date.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused, expired, or no longer needed product must be discarded according to local governmental regulations. Single-use units must be discarded immediately after application, including any remaining liquid. Do not dispose of the solution by flushing it down a toilet or sink unless explicitly directed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Benox found in:

A-Z Index: